pPJV7630

What it is

pPJV7630 is a DNA vaccine for HSV-2, described in its registry record as therapeutic and sponsored by PowderMed. In both registered trials it was administered by PMED; the second record describes this as particle-mediated epidermal delivery using the PowderMed ND10 system.

Where it stands

NCT00274300 was a phase 1, two-center, open-label, dose-escalating study of safety, tolerability and immunogenicity in patients with recurrent genital herpes caused by HSV-2. It is listed as completed in 2005 with an enrollment figure of 36 that the record does not mark as actual or estimated, and no results are posted. NCT00310271 was a phase 1 safety and tolerability study of pPJV7630 given with pPJV2012 in HSV-2 seronegative healthy volunteers; the trial title describes a DNA vaccine with a DNA-encoded immunostimulator. It is listed as completed in 2006 with an enrollment figure of 42 that the record does not mark as actual or estimated, and no results are posted. A ClinicalTrials.gov search on 2026-09-27 for records naming pPJV7630 returned these 2 records, and none had an ongoing status.

What this does and doesn’t mean

These were phase 1 studies focused on safety, tolerability and immune response, so their existence does not show that the vaccine reduced herpes outbreaks or prevented infection. No results from either trial are posted on the registry or reported in the sources here.